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Abstract
GalliPro® is the trade name for a feed additive based on viable cells of a strain of Bacillus subtilis
intended for use as a zootechnical additive (gut ﬂora stabiliser) in feed for chickens for fattening. The
product is currently authorised for use in chickens for fattening. This opinion concerns the renewal of
this authorisation. Bacillus subtilis is considered by EFSA to be suitable for the qualiﬁed presumption of
safety (QPS) approach to establish the safety for the target species, consumers and the environment.
The identity of the strain present in the additive was established and evidence was provided on the
lack of toxigenic potential as well as acquired antibiotic resistance determinants to antibiotics of human
and veterinary importance. Accordingly, this strain is presumed safe for the target species, consumers
of products derived from animals fed the additive and the environment. Since no concerns are
expected from other components of the additive, GalliPro® is considered safe for the target species,
consumers and the environment. The applicant has provided evidence that the additive currently in the
market complies with the existing conditions of authorisation. The FEEDAP Panel conﬁrms its previous
conclusions that GalliPro® is safe for the target species; consumers of products from animals fed the
additive and the environment. GalliPro® should be considered a potential respiratory sensitiser. In the
absence of data, the FEEDAP Panel cannot conclude on the potential of GalliPro® for skin and eyes
irritancy and dermal sensitisation.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 14 of that Regulation speciﬁes that for
products authorised according to Article 9, an application for renewal shall be submitted in accordance
with Article 7, at the latest one year before the expiry date of the authorisation.
The European Commission received a request from Chr. Hansen A/S2 for renewal of the
authorisation of the product GalliPro®3 (Bacillus subtilis DSM 17299 ), when used as a feed additive for
chickens for fattening (category: zootechnical additive; functional group: gut ﬂora stabiliser).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 14(1)
(renewal of an authorised feed additive). EFSA received directly from the applicant the technical
dossier in support of this application. The particulars and documents in support of the application were
considered valid by EFSA as of 7 December 2016.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product GalliPro® (Bacillus subtilis DSM 17299), when used under the proposed conditions of use (see
Section 3.1.3).
1.2. Additional information
EFSA has issued several opinions on the safety and efﬁcacy of GalliPro® for chickens for fattening
and on its compatibility with coccidiostats (EFSA, 2006, 2007a, 2008, 2009, 2010). In 2011, the EFSA
Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) produced an opinion on
the modiﬁcation to the formulation of GalliPro® and on its compatibility with formic acid (EFSA FEEDAP
Panel, 2011).
The product is currently authorised for use in chickens for fattening.5 It was originally authorised
under the tradename 035 as a product containing a minimum guaranteed concentration of Bacillus
subtilis DSM 17299 of 1.6 9 109 colony forming units (CFU) per gram of additive, intended for use in
feed for chickens for fattening at a minimum concentration of 8 9 108 CFU/kg feed and a maximum
concentration of 1.6 9 109 CFU/kg feed. In 2011, the authorisation was amended to increase the
minimum guaranteed concentration of Bacillus subtilis DSM 17299 to 1.6 9 1010 CFU/g of additive and
to allow the simultaneous use with formic acid. In an amendment in 2012, the maximum concentration
in feed was removed. Other amendments in 2010 and 2011 regarded the authorisation of use in the
presence of the coccidiostats diclazuril, halofuginone, robenidine, decoquinate, narasin/nicarbazin,
lasalocid sodium, maduramycin ammonium, monensin sodium, narasin, salinomycin sodium,
semduramycin sodium.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Chr. Hansen A/S, 10-12 Boege Alle, DK 2970, Hoersholm, Denmark.
3 The Applicant also markets the product under other trade names: 035, GalliPro® Max, GalliPro® 10,
5 Commission Regulation (EC) No 1137/2007 of 1 October 2007 concerning the authorisation of Bacillus subtilis (O35) as a feed
additive. OJ L, 256, 2.10.2007, p. 5; Commission Regulation (EC) No 203/2009 of 16 March 2009 amending Regulation (EC) No
1137/2007 as regards the use of the feed additive Bacillus subtilis (O35) in feed containing decoquinate and narasin/nicarbazin,
OJ L 71, 17.3.2009, p. 11; Commission Regulation (EU) No 515/2010 of 15 June 201 amending Regulation (EC) No 1137/2007
as regards the use of the feed additive Bacillus subtilis (O35) in feed containing lasalocid sodium, maduramycin ammonium,
monensin sodium, narasin, salinomycin sodium and semduramycin sodium, OJ L 150, 16.6.2010, p. 44; Commission
Implementing Regulation (EU) No 881/2011 of 2 September 2011 amending Regulation (EC) No 1137/2007 as regards the
additive composition of the preparation of Bacillus subtilis DSM 17299 (holder of authorisation Chr. Hansen A/S) and its use in
feed containing formic acid, OJ L 228, 3.9.2011, p. 9; COMMISSION IMPLEMENTING REGULATION (EU) No 1018/2012 of 5
November 2012 amending Regulations (EC) No 232/2009, (EC) No 188/2007, (EC) No 186/2007, (EC) No 209/2008, (EC)
No 1447/2006, (EC) No 316/2003, (EC) No 1811/2005, (EC) No 1288/2004, (EC) No 2148/2004, (EC) No 1137/2007, (EC)
No 1293/2008, (EC) No 226/2007, (EC) No 1444/2006, (EC) No 1876/2006, (EC) No 1847/2003, (EC) No 2036/2005, (EC)
No 492/2006, (EC) No 1200/2005, and (EC) No 1520/2007 as regards the maximum content of certain micro-organisms in
complete feedingstuffs; OJ L 307, 7.11.2012, p. 56.
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2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier6 in support of the request for the renewal of the authorisation for the use of GalliPro® (Bacillus
subtilis DSM 17299) as a feed additive.
The European Union Reference Laboratory (EURL) considered that the conclusions and
recommendations reached in the previous assessment are valid and applicable for the current
application.7
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of GalliPro®
(Bacillus subtilis DSM 17299) is in line with the principles laid down in Regulation (EC) No 429/20088
and the relevant guidance documents: Guidance on the assessment of bacterial susceptibility to
antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012), Guidance on the
renewal of the authorisation of feed additives (EFSA FEEDAP Panel, 2013) and Guidance on the
assessment of the toxigenic potential of Bacillus species used in animal nutrition (EFSA FEEDAP Panel,
2014).
3. Assessment
The additive GalliPro® consists of viable spores of Bacillus subtilis DSM 17299 and is currently
authorised as a zootechnical additive (gut ﬂora stabiliser) in feed for chickens for fattening. The
applicant is asking for the renewal of the authorisation.
3.1. Characterisation
3.1.1. Characterisation of the additive
GalliPro® is currently authorised as a solid preparation with a minimum guaranteed concentration of
B. subtilis DSM 17299 of 1.6 9 1010 CFU/gram of additive.9
The additive is composed of 3% spores concentrate, 96% carrier (limestone/calcium carbonate) and
1% of anticaking agent (Kieselgur). The applicant stated that no changes in the manufacturing process or
composition of the additive have been introduced since the last authorisation. Compliance with
speciﬁcations was conﬁrmed by the analysis of three recent batches produced (range: 2.2–2.3 9 1010
CFU/g, average: 2.3 9 1010 CFU/g).10
Data from the same batches conﬁrmed compliance with speciﬁcations for total coliforms
(< 103 CFU/g), Escherichia coli (< 10 CFU/g), yeasts and ﬁlamentous fungi (< 103 CFU/g), and
Salmonella spp. (absent in 25 g).10 Data from other three recent batches conﬁrmed compliance
with speciﬁcations for undesirable substances. Values were: aﬂatoxin B1 (< 0.64 lg/kg),11
mercury (0.0106–0.0146 mg/kg, lead (0.458–0.850 mg/kg), cadmium (0.033–0.092 mg/kg), arsenic
(0.535–0.892 mg/kg).12
The dusting potential of three batches of the additive was tested with a Heubach dustmeter and
showed values in the range 2.3–2.5 g/m3.13
6 FEED dossier reference: FAD-2016-0059.
7 The full report is available on the EURL website: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports/fad-2005-
0021?search&form-return
8 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
9 Technical dossier/Section II.
10 Technical dossier/Section II/Annex II.1.3b.
11 Limit of quantiﬁcation.
12 Technical dossier/Section II/Annex II.1.4.1.
13 Technical dossier/Supplementary information July 2018/Annex II.1.5b.v2.
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3.1.2. Characterisation of the active agent
The active agent of GalliPro® is deposited in the German Collection of Microorganisms and cell
Cultures with the accession number DSM 17299.14
Strain identiﬁcation was achieved by pulsed-ﬁeld gel electrophoresis (PFGE) after
cleavage with restriction enzymes. The lack of resistance to relevant antibiotics and of toxigenic
potential have been demonstrated following the guidance on the assessment of bacterial
susceptibility to antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012) and
the guidance on the assessment of the toxigenic potential of Bacillus species used in animal nutrition
(EFSA FEEDAP Panel, 2014).
3.1.3. Conditions of use
GalliPro® is currently authorised in feed for chickens for fattening at the minimum inclusion level of
8 9 108 CFU/kg complete feedingstuff.
It is allowed to be used simultaneously with the coccidiostats: diclazuril, halofuginone, robenidine,
decoquinate, narasin/nicarbazin, lasalocid sodium, maduramycin ammonium, monensin sodium,
narasin, salinomycin sodium and semduramycin sodium, and with formic acid.
The applicant proposes to maintain the same conditions of use.
3.2. Safety
3.2.1. Safety for the target species, consumers and the environment
The bacterial species B. subtilis is considered by EFSA to be suitable for the qualiﬁed presumption
of safety (QPS) approach to safety assessment (EFSA, 2007a,b; EFSA BIOHAZ Panel, 2017). This
approach requires the identity of the active agent to be established and evidence that the strain lacks
of toxigenic potential and does not show resistance to antibiotics of human and veterinary importance.
The identity of the GalliPro® strain was established as B. subtilis and the lack of toxigenic potential and
of acquired antibiotic resistance determinants to relevant antibiotics was established. Accordingly, this
strain is considered by EFSA to be suitable for the QPS approach to safety and is presumed safe for
the target species, consumers of products derived from animals fed the additive and the environment.
Since no concerns are expected from other components of the additive, GalliPro® is also considered
safe for the target species, consumers of products from animals fed the additive and the environment.
3.2.2. Safety for the user
In its original opinion (EFSA, 2006), the FEEDAP Panel concluded that the additive due to its
proteinaceous nature may induce respiratory sensitisation.
The dustiness of the preparation tested indicated a potential for users to be exposed via inhalation.
No additional information has been provided in this application. No data are available on skin/eye
irritation or skin sensitisation. In the absence of data, the FEEDAP Panel cannot conclude on the
potential of GalliPro® for skin and eyes irritancy and dermal sensitisation.
3.2.3. Further evidence
The applicant declares to have a post-market monitoring system in place and that no adverse
effects or complaints have been reported by users of the product or workers handling it during
production process.19
The applicant conducted a literature search on the safety of GalliPro® using several databases:
Academic Oneﬁle, Food Science Source, Agris and PubMed.20 The search included the terms:
14 Technical dossier/Supplementary information July 2018/Annex II.2.1.2a.v2.
19 Technical dossier/Section III.
20 Technical dossier/Supplementary information July 2018/Annexes III.3 and Supplementary information October 2018.
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Bacillus subtilis, DSM 17299, , GalliPro, , safety, toxicity and adverse effect. The search
covered the period 2007–2018 and identiﬁed 67 potential relevant publications (Appendix A). The
majority of the experiments were not designed to assess the safety per se of the additive, but to
investigate the effect(s) of the additive on zootechnical performance. Some included also health
parameters (i.e. blood biochemistry, mortality), and one in particular investigated the immune response
of Salmonella challenged chickens fed diets containing Gallipro®. The results did not evidence any
adverse effect of the additive on the immune response of birds, either in challenged or non-contaminated
birds (Sadeghi et al., 2015). A second study tested the effects of the supplementation of an additive
containing the strain under assessment on tibial bone characteristics in chickens (e.g.
thickness of the medial and lateral wall of the tibia, phosphorous content) . Results
did not reveal any adverse effect on the parameters measured.
Therefore, the FEEDAP Panel concludes that there is no new evidence that would lead the Panel to
reconsider its previous conclusions on the safety of the product for target species, consumers, users
and the environment under the authorised conditions of use.
3.2.4. Efﬁcacy
The present application for renewal of the authorisation does not include a proposal for amending
or supplementing the conditions of the original authorisation that would have an impact on the efﬁcacy
of the additive. Therefore, there is no need for assessing the efﬁcacy of the additive in the context of
the renewal of the authorisation.
3.3. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation21 and Good
Manufacturing Practice.
4. Conclusions
The applicant has provided evidence that the additive currently in the market complies with the
existing conditions of authorisation.
The FEEDAP Panel conﬁrms its previous conclusions that GalliPro® is safe for the target species,
consumers of products from animals fed the additive and the environment. GalliPro® should be
considered a potential respiratory sensitiser. In the absence of data, the FEEDAP Panel cannot
conclude on the potential of GalliPro® for skin and eyes irritancy and dermal sensitisation.
Documentation provided to EFSA/Chronology
Date Event
29/09/2016 Dossier received by EFSA. GalliPro. Submitted by Chr. Hansen A/S
24/10/2016 Reception mandate from the European Commission
07/12/2016 Application validated by EFSA – Start of the scientiﬁc assessment
07/03/2017 Comments received from Member States
10/10/2017 Spontaneous submission of information by the applicant. Issues: safety for the consumer
05/02/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety for target
species, consumer, user and environment
19/07/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
12/10/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: Safety
29/10/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
01/04/2019 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
21 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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